ALK and non-small cell lung carcinoma: Lorlatinib, as the unique third-generation ALK-TKIs, when selected as the first-line treatment, achieved 90% ORR from all NSCLC patients and 66.7% ORR from the patients with central nervous system metastases (Solomon et al., 2018a).